Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Polypoidal Choroidal Vasculopathy: A Distinct Disease or Manifestation of Many?

Balaratnasingam, Chandrakumar MD, PhD*,†,‡; Lee, Won-Ki MD§; Koizumi, Hideki MD, PhD; Dansingani, Kunal MD*,†; Inoue, Maiko MD*,†; Freund, K. Bailey MD*,†,**

doi: 10.1097/IAE.0000000000000774

*LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat hospital, New York, NY

†Vitreous-Retina-Macula Consultants of New York, NY

‡Centre for Ophthalmology and Visual Sciences, Lions Eye Institute, University of Western Australia, Perth, Australia

§Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea

¶Department of Ophthalmology, Tokyo Women's Medical University, Japan

**Department of Ophthalmology, New York University School of Medicine, New York, NY

Supported by LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital/North Shore Long Island Jewish Hospital, New York, NY, and The Macula Foundation, Inc., New York, NY.

K. B. Freund is a consultant to Genentech, ThromboGenics, Ohr Pharmaceutical, Optos, Optovue, and Heidelberg Engineering (honorarium for each). H. Koizumi reports grants from The Ministry of Education, Culture, Sports, Science and Technology-Japan, during the conduct of the study; personal fees from Novartis Pharma K.K., personal fees from Bayer Yakuhin, Ltd., personal fees from Santen Pharmaceutical Inc., personal fees from Alcon Japan, Ltd., personal fees from HOYA Corp., personal fees from Topcon Co., Ltd., personal fees from Canon Inc., personal fees from Wakamoto Pharmaceutical Co., Ltd., personal fees from Senju Pharmaceutical Co., Ltd., personal fees from NIDEK Co., Ltd., outside the submitted work. Dr. W.-K. Lee is a consultant to Novartis, Bayer, Allergan, Alcon, and Santen (honorarium for each). The other authors have no conflicting interests to disclose.

© 2016 by Ophthalmic Communications Society, Inc.